OBJECTIVE: To evaluate the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) after progression under sorafenib treatment. METHODS: Sunitinib was administered at 37.5 mg daily (4-weeks-on/2-weeks-off schedule) after progression under sorafenib treatment. Adverse events (AEs) were assessed using NCI-CTCAE v3.0, and tumor response was evaluated according to RECIST. Data were analyzed retrospectively. RESULTS: Eleven patients with metastatic disease were treated. Seven patients (64%) presented with no liver cirrhosis, including 3 patients with a history of liver transplantation. The first radiological follow-up showed stable disease in 40% of patients after marked radiological progression under sorafenib. The median time to progression was 3.2 months. Treatment was discontinued due to radiological progression (n = 9) or AEs (n = 2; hemorrhages) in all patients after 3.5 months. The median overall survival was 8.4 months. All patients with Child-Pugh class B liver cirrhosis suffered a clinical deterioration of liver function and died within 4 months due to tumor progression. CONCLUSIONS: Sunitinib provided modest antitumor activity in patients with advanced HCC after progression under sorafenib treatment. Patients with Child-Pugh class B liver cirrhosis might not receive a clinical benefit from this second-line approach. Hemorrhagic complications may represent a clinically relevant problem of sunitinib in patients with advanced HCC.
OBJECTIVE: To evaluate the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) after progression under sorafenib treatment. METHODS:Sunitinib was administered at 37.5 mg daily (4-weeks-on/2-weeks-off schedule) after progression under sorafenib treatment. Adverse events (AEs) were assessed using NCI-CTCAE v3.0, and tumor response was evaluated according to RECIST. Data were analyzed retrospectively. RESULTS: Eleven patients with metastatic disease were treated. Seven patients (64%) presented with no liver cirrhosis, including 3 patients with a history of liver transplantation. The first radiological follow-up showed stable disease in 40% of patients after marked radiological progression under sorafenib. The median time to progression was 3.2 months. Treatment was discontinued due to radiological progression (n = 9) or AEs (n = 2; hemorrhages) in all patients after 3.5 months. The median overall survival was 8.4 months. All patients with Child-Pugh class B liver cirrhosis suffered a clinical deterioration of liver function and died within 4 months due to tumor progression. CONCLUSIONS:Sunitinib provided modest antitumor activity in patients with advanced HCC after progression under sorafenib treatment. Patients with Child-Pugh class B liver cirrhosis might not receive a clinical benefit from this second-line approach. Hemorrhagic complications may represent a clinically relevant problem of sunitinib in patients with advanced HCC.
Authors: Justin W Ady; Jacqueline Heffner; Kelly Mojica; Clark Johnsen; Laurence J Belin; Damon Love; Chin-Tung Chen; Amudhan Pugalenthi; Elizabeth Klein; Nanhai G Chen; Yong A Yu; Aladar A Szalay; Yuman Fong Journal: Surgery Date: 2014-06-21 Impact factor: 3.982
Authors: R A Pazo-Cid; M Lanzuela; G Esquerdo; J L Pérez-Gracia; A Antón; G Amigo; J Martínez Trufero; A L García-Otín; P Martín-Duque Journal: Clin Transl Oncol Date: 2012-07-18 Impact factor: 3.405
Authors: Aaron T Wecksler; Sung Hee Hwang; Jun-Yan Liu; Hiromi I Wettersten; Christophe Morisseau; Jian Wu; Robert H Weiss; Bruce D Hammock Journal: Cancer Chemother Pharmacol Date: 2014-11-21 Impact factor: 3.333